# US 2026/0061049 A1 · Self-assembling peptide scaffold

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061049 A1
- Document ID: US20260061049A1
- Status: Published application
- Kind: A1
- Application number: 19/370,520
- Filed: 2025-10-27
- Published: 2026-03-05
- Earliest claimed: 2025-10-27
- Assignees: Hexamer Therapeutics, Inc.
- Applicants: Hexamer Therapeutics, Inc.
- Inventors: Keith Douglas Miller
- Web page: https://patentgrep.com/patent/US20260061049A1

## CPC

- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/001: {by chemical synthesis}
- A61K 2039/6031: {Proteins}
- A61K 2039/64: {characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units}
- C07K 2319/735: containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure describes a peptide scaffold for producing vaccines. The peptide scaffold includes a peptide that self-assembles into a hapten carrier (hC) includes amphipathic alpha-helices. The peptide includes heptad repeats following a specific pattern. The hC further includes hapten or an agent conjugated to it, and optionally the hC includes one or more T-cell epitopes at the N- and/or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions including immunogenic compositions including the hapten-hC or agent-hC conjugate.

## Claims

### Claim 1

A method of protecting a subject from a disease, wherein the method comprises administering to the subject in need thereof, an effective amount of a peptide conjugate comprising an oligomer and one or more haptens, wherein the hapten induces an immune response to protect a subject from the disease, and wherein the oligomer comprises a peptide comprising one or more heptads:
wherein the heptad has the following amino acid sequence: hwxhxyz (SEQ ID NO: 19;
wherein the peptide comprises the following amino acid sequence pattern:
(SEQ ID NO: 20)
(hwxhxyz)n,
and wherein:
h is I, L, V, F, W, Y, M, W, G, or A;
w is G, R, A, N, Q, H, S, D, E, K or T;
x is R, S, N, Q, A, G, T, D, E, K, H, or C;
y is K, H, C, D, E, R, W, Y, Q, N, or a non-natural amino acid or molecule containing reactive groups amenable to covalent coupling;
z is A, D, H, S, E, R, N, Q, K, or G; and
n is 2 to 10.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 3

A method of treating a subject having a disease, wherein the method comprises administering to the subject in need thereof, an effective amount of a peptide conjugate comprising an oligomer and one or more haptens, wherein the hapten induces an immune response to treat the subject and wherein the oligomer comprises a peptide comprising one or more heptads:
wherein the heptad has the following amino acid sequence: hwxhxyz (SEQ ID NO: 19;
wherein the peptide comprises the following amino acid sequence pattern:
(SEQ ID NO: 20)
(hwxhxyz)n,
and wherein:
h is I, L, V, F, W, Y, M, W, G, or A;
w is G, R, A, N, Q, H, S, D, E, K or T;
x is R, S, N, Q, A, G, T, D, E, K, H, or C;
y is K, H, C, D, E, R, W, Y, Q, N, or a non-natural amino acid or molecule containing reactive groups amenable to covalent coupling;
z is A, D, H, S, E, R, N, Q, K, or G; and
n is 2 to 10.

### Claim 4 (depends on 3)

The method of claim 3, wherein the subject is a mammal.
